ID: ALA3397802

Max Phase: Preclinical

Molecular Formula: C27H25F2NO3

Molecular Weight: 449.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  O[C@@H]1C[C@@H](C(c2ccc(F)cc2)c2ccc(F)cc2)OC[C@H]1NCc1ccc2occc2c1

Standard InChI:  InChI=1S/C27H25F2NO3/c28-21-6-2-18(3-7-21)27(19-4-8-22(29)9-5-19)26-14-24(31)23(16-33-26)30-15-17-1-10-25-20(13-17)11-12-32-25/h1-13,23-24,26-27,30-31H,14-16H2/t23-,24-,26+/m1/s1

Standard InChI Key:  GDMBCKPJRQVABL-MZKUHISZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 449.50

Molecular Weight (Monoisotopic): 449.1803

AlogP: 5.15

#Rotatable Bonds: 6

Polar Surface Area: 54.63

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.38

CX LogP: 4.82

CX LogD: 3.80

Aromatic Rings: 4

Heavy Atoms: 33

QED Weighted: 0.43

Np Likeness Score: 0.25

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature